OBJECTIVE： To evaluate the economical efficiency of 3 therapeutic regimens for hyperthyroidism. METHODS： Medical records of 564 hyperthyroid outpatients were selected from our hospital in 2016， and they were divided into group A （185 cases）， group B（191 cases） and group C（188 cases） according to drug use. Group A received Thiamazole tablets 2-4 tablet，once asthecondition gradually reduce th amount to 0.5-2 tablets orally； group B received Thiamazole tablets （cusage and dosage are the same as group A）+Yikang pills 6 g，bid orally； group C received Thiamazole tablets （cusage and dosage are the same as group A）+Xiakucao tablets 6 tablets，bid orally. The treatment courses of 3 groups lasted for 10 months. Clinical efficacy the occurrence of ADR and recurrence were observed in 3 groups.The pharmacoeconomic cost-effectiveness analysis was adopted for the economic evaluation of 3 therapeutic regimens. RESULTS： The tolal response rates of group A， B， C were 94.06％， 95.29％， 95.75％， respectively； total incidence of ADR were 11.36％， 10.48％， 10.11％； there was no statistical significance （P＞0.05）. No recurrence occurred in the 3 groups. The average cost of 3 groups were 633.80， 3 548.89， 3 596.00 yuan， respectively. The cost of group A was the lowest. The results of sensitivity analysis were also that the cost of group A was the lowest. CONCLUSIONS： 3 therapeutic regimens show good therapeutic efficacy and safety for hyperthyroidism， among which thiamazole alone has relatively higher pharmacoeconomic significance.